Dr. William Eaves II, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 935
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Louisiana State University School of Medicine in Shreveport
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
LA license 021588
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Willis Knighton Medical Center Shreveport, LA
- North Caddo Medical Center Vivian, LA
Medical groups
- Wkmc Cardiovascular Consultants (33 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 935
- Services billed
- 3,561
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 722 | 458 |
| Established patient office or other outpatient visit, 30-39 minutes | 568 | 395 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 324 | 309 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 196 | 189 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 191 | 191 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 128 | 68 |
| Ultrasound of leg arteries or artery grafts | 125 | 103 |
| Ultrasound study of arm and leg arteries | 123 | 100 |
| Ultrasound of both sides of head and neck blood flow | 121 | 114 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 102 | 95 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Shreveport, LA | 408 |
| Eliquis (apixaban) Other prescribers in Shreveport, LA | 354 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Shreveport, LA | 336 |
| Diltiazem 24hr Er (Cd) (diltiazem hcl) Other prescribers in Shreveport, LA | 260 |
| Atorvastatin Calcium Other prescribers in Shreveport, LA | 227 |
| Entresto (sacubitril/valsartan) Other prescribers in Shreveport, LA | 184 |
| Losartan Potassium Other prescribers in Shreveport, LA | 158 |
| Amlodipine Besylate Other prescribers in Shreveport, LA | 158 |
| Rosuvastatin Calcium Other prescribers in Shreveport, LA | 153 |
| Carvedilol Other prescribers in Shreveport, LA | 143 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 90 payments worth $2,245 in total to this clinician.
| Boston Scientific Corporation | $418 |
|---|---|
| Shockwave Medical, Inc | $290 |
| Stryker Corporation | $238 |
| Kestra Medical Technology Services, Inc. | $237 |
| Abiomed | $229 |
| Itamar Medical Inc | $154 |
| Endologix LLC | $107 |
| Merck Sharp & Dohme LLC | $89.44 |
| Food and Beverage | $2,245 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 10 companies. The companies reported $266,424 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
Amgen Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A lowinterventional prospective longitudinal cohort study to collect digital functional assessments and evaluate symptoms in study participants with chronic heart failure
Pfizer Inc. - Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENT…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.